 70 subjects received BCG intradermally at Study Day -42, then at Study Day 0 were randomized to receive AERAS-404 50 mcg H4500 nmol IC31 intramuscularly as a 3-dose N30 or 2-dose N30 regimen, or placebo N10. Subjects were vaccinated on Study Days 0, 56, and 231, and followed through Study Day 259. 